Skip to main content
Log in

The application of proton pump inhibitors in cardiovascular disease needs to be individualized

Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Maret-Ouda J, Santoni G, Xie S, Rosengren A, Lagergren J. Proton pump inhibitor and clopidogrel use after percutaneous coronary intervention and risk of major cardiovascular rvents. Cardiovasc Drugs Ther. 2021. https://doi.org/10.1007/s10557-021-07219-6.

  2. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168–71.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Shi WC, Gao SD, Yang JG et al. Impact of proton pump inhibitors on clinical outcomes in patients after acute myocardial infarction: a propensity score analysis from China Acute Myocardial Infarction (CAMI) registry. J Geriatr Cardiol. 2020;17(11):659–65.

    PubMed  PubMed Central  Google Scholar 

  4. Xie J, Chen Q, He D. Pre-existing Proton Pump Inhibitor Treatment and Short-Term Prognosis of Acute Myocardial Infarction Patients. Front Cardiovasc Med. 2022;9:919716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Khawaja M, Thakker J, Kherallah R et al. Antacid therapy in coronary artery disease and heart failure: proton pump inhibitors vs. H2 receptor blockers. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07358-4.

Download references

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to De-Gang Mo.

Ethics declarations

Conflicts of interests

The authors report no relationships that could be construed as a conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, XL., Liu, JH. & Mo, DG. The application of proton pump inhibitors in cardiovascular disease needs to be individualized. Cardiovasc Drugs Ther 36, 1247–1248 (2022). https://doi.org/10.1007/s10557-022-07395-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-022-07395-z

Navigation